Skip to main content
Journal cover image

The SLCO1B1*5 genetic variant is associated with statin-induced side effects.

Publication ,  Journal Article
Voora, D; Shah, SH; Spasojevic, I; Ali, S; Reed, CR; Salisbury, BA; Ginsburg, GS
Published in: J Am Coll Cardiol
October 20, 2009

OBJECTIVES: We sought to identify single nucleotide polymorphisms associated with mild statin-induced side effects. BACKGROUND: Statin-induced side effects can interfere with therapy. Single nucleotide polymorphisms in cytochrome P450 enzymes impair statin metabolism; the reduced function SLCO1B1*5 allele impairs statin clearance and is associated with simvastatin-induced myopathy with creatine kinase (CK) elevation. METHODS: The STRENGTH (Statin Response Examined by Genetic Haplotype Markers) study was a pharmacogenetics study of statin efficacy and safety. Subjects (n = 509) were randomized to atorvastatin 10 mg, simvastatin 20 mg, or pravastatin 10 mg followed by 80 mg, 80 mg, and 40 mg, respectively. We defined a composite adverse event (CAE) as discontinuation for any side effect, myalgia, or CK >3x upper limit of normal during follow-up. We sequenced CYP2D6, CYP2C8, CYP2C9, CYP3A4, and SLCO1B1 and tested 7 reduced function alleles for association with the CAE. RESULTS: The CAE occurred in 99 subjects (54 discontinuations, 49 myalgias, and 9 CK elevations). Sex was associated with CAE (percent female in CAE vs. no CAE groups, 66% vs. 50%, p < 0.01). SLCO1B1*5 was associated with CAE (percent with > or = 1 allele in CAE vs. no CAE groups, 37% vs. 25%, p = 0.03) and those with CAE with no significant CK elevation (p < or = 0.03). Furthermore, there was evidence for a gene-dose effect (percent with CAE in those with 0, 1, or 2 alleles: 19%, 27%, and 50%, trend p = 0.01). Finally, the CAE risk appeared to be greatest in those carriers assigned to simvastatin. CONCLUSIONS: SLCO1B1*5 genotype and female sex were associated mild statin-induced side effects. These findings expand the results of a recent genome-wide association study of statin myopathy with CK >3x normal to milder, statin-induced, muscle side effects.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Am Coll Cardiol

DOI

EISSN

1558-3597

Publication Date

October 20, 2009

Volume

54

Issue

17

Start / End Page

1609 / 1616

Location

United States

Related Subject Headings

  • Simvastatin
  • Pyrroles
  • Pravastatin
  • Polymorphism, Single Nucleotide
  • Organic Anion Transporters
  • Muscular Diseases
  • Middle Aged
  • Male
  • Liver-Specific Organic Anion Transporter 1
  • Hypolipidemic Agents
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Voora, D., Shah, S. H., Spasojevic, I., Ali, S., Reed, C. R., Salisbury, B. A., & Ginsburg, G. S. (2009). The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol, 54(17), 1609–1616. https://doi.org/10.1016/j.jacc.2009.04.053
Voora, Deepak, Svati H. Shah, Ivan Spasojevic, Shazia Ali, Carol R. Reed, Benjamin A. Salisbury, and Geoffrey S. Ginsburg. “The SLCO1B1*5 genetic variant is associated with statin-induced side effects.J Am Coll Cardiol 54, no. 17 (October 20, 2009): 1609–16. https://doi.org/10.1016/j.jacc.2009.04.053.
Voora D, Shah SH, Spasojevic I, Ali S, Reed CR, Salisbury BA, et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol. 2009 Oct 20;54(17):1609–16.
Voora, Deepak, et al. “The SLCO1B1*5 genetic variant is associated with statin-induced side effects.J Am Coll Cardiol, vol. 54, no. 17, Oct. 2009, pp. 1609–16. Pubmed, doi:10.1016/j.jacc.2009.04.053.
Voora D, Shah SH, Spasojevic I, Ali S, Reed CR, Salisbury BA, Ginsburg GS. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol. 2009 Oct 20;54(17):1609–1616.
Journal cover image

Published In

J Am Coll Cardiol

DOI

EISSN

1558-3597

Publication Date

October 20, 2009

Volume

54

Issue

17

Start / End Page

1609 / 1616

Location

United States

Related Subject Headings

  • Simvastatin
  • Pyrroles
  • Pravastatin
  • Polymorphism, Single Nucleotide
  • Organic Anion Transporters
  • Muscular Diseases
  • Middle Aged
  • Male
  • Liver-Specific Organic Anion Transporter 1
  • Hypolipidemic Agents